P2RY1 and type 2 diabetes mellitus: In addition, the prevalence of ADP receptor blocker nonresponders did not differ significantly in clopidogrel-treated T2D patients compared to clopidogrel-treated ND patients (sample 1: 63.6% versus 72.7%, NS; sample 2: 54.6 versus 50.0%, NS).